Home / Pharmacy / Collaborate and capitalise on new sciences

Collaborate and capitalise on new sciences

Costs per molecule are still rising relentlessly and the number of new medicines reaching the market remains broadly flat. Why?

Our research suggests a distinct problem is scientific and we think three changes would make a big difference.

  • The industry should rebalance its expenditure and invest more in the early part of the R&D process to understand the molecular basis of disease and the role specific mechanisms play.
  • Companies should become more selective about the therapeutic areas they cover and bolster their expertise by hiring or collaborating with the best people in their chosen fields of research.
  • Every company should devise a clear path to clinical proof of concept for all compounds entering development and test them in humans as soon as possible, using the best tools for selecting subjects and endpoints.

Check Also

Rakhi Creation Is One of the Traditional Profitable Businesses

Rakhi creation is one of the most low-cost and homely-based business. It is an one …

Bitnami